Millennium Management
ABCL icon

Millennium Management’s AbCellera Biologics ABCL Stock Holding History

Millennium Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-297,200
Closed -$3.17M – 7004
2022
Q2 		$3.17M Buy
+297,200
New +$2.52M ﹤0.01% 3239

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management's ABCL Position: Q1 2026 in Review

Millennium Management reduced its AbCellera Biologics (ABCL) stake by 27% in Q1 2026, selling an estimated $1.72M and leaving 1,294,574 shares worth $4.52M. The position accounts for ﹤0.01% of the portfolio, ranked #3067.

Millennium Management first reported a position in ABCL in Q4 2020 and has held it in 22 quarters since. The position peaked at $31.5M in Q2 2022. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Millennium Management held 1,294,574 shares of AbCellera Biologics worth $4.52M as of Q1 2026.
  • Millennium Management sold 478,965 AbCellera Biologics shares in Q1 2026, an estimated $1.72M.
  • AbCellera Biologics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3067 holding.
  • Millennium Management first reported a position in AbCellera Biologics in Q4 2020 and has held it in 22 quarters since.
  • Millennium Management's AbCellera Biologics position peaked at $31.5M in Q2 2022.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.